Company intelligence / Profile preview

instED

Bridgewater, New Jersey, United Statesinsted.us ↗

Ownership: Private
Development stage: Other

Overview

Insmed develops life-transforming medicines targeting serious and rare diseases. Its lead commercial product, Arikayce, treats NTM lung infections caused by MAC. The pipeline includes brensocatib in Phase 3 trials for non-CF bronchiectasis and TPIP in clinical development for pulmonary hypertension-related indications. The company also advances novel biologics and gene therapies using proprietary platforms focused on reducing immunogenicity and improving efficacy.

Therapeutic areas: Infectious DiseasesPulmonologyCardiovascular
Modalities: Small moleculeBiologicMonoclonal antibodyGene therapyProtein (therapeutic protein)Liposomal drug delivery
Industry: Biotech

Beyond the preview

Go deeper on instED.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on instED.

Explore the full profile